logo
How to Lay a Block Paving Driveway: Step by Step Guide

How to Lay a Block Paving Driveway: Step by Step Guide

A block paving driveway can completely transform your home's curb appeal, enhancing its value and functionality. Whether you're looking for durability, low maintenance, or aesthetic charm, block paving offers it all. But to achieve the best results, proper planning and expert installation are essential. If you're in Swindon, this step-by-step guide will help you understand the process and benefits of installing a block paving driveway. Plus, we'll show you why leaving this project to the professionals at Driveway Swindon is the smartest move.
Block paving involves individual stone or concrete blocks interlocked to create a paved surface. These surfaces are known for their strength, style, and versatility. Here's why homeowners in Swindon love block paving: Durable and long-lasting: Properly installed block paving can handle heavy vehicles and resist wear-and-tear for decades.
Properly installed block paving can handle heavy vehicles and resist wear-and-tear for decades. Aesthetic variety: Choose from various colors, patterns, and textures to match your style.
Choose from various colors, patterns, and textures to match your style. Low maintenance: With occasional cleaning and weed control, your driveway stays pristine.
With occasional cleaning and weed control, your driveway stays pristine. Environmental benefit: Permeable options improve drainage and reduce flooding risks.
Now, let's break down the process into manageable steps.
Before starting any construction, you'll need a solid plan. Here's what to consider: Measure the area: Determine the size of the driveway you need.
Determine the size of the driveway you need. Choose materials: Block paving stones come in different materials, from concrete to clay. Consider aesthetics, durability, and your budget.
Block paving stones come in different materials, from concrete to clay. Consider aesthetics, durability, and your budget. Decide on the pattern: Common patterns include herringbone, stretcher bond, and basketweave. Each offers unique visual appeal and load distribution advantages.
Common patterns include herringbone, stretcher bond, and basketweave. Each offers unique visual appeal and load distribution advantages. Account for drainage: UK regulations require driveways to have proper drainage. Permeable blocks are a great option to comply with sustainable drainage systems (SuDS).
At Driveway Swindon, our experts can help you design a driveway tailored to your needs while meeting local planning regulations.
Proper site preparation ensures the driveway's longevity. The process includes: Marking the area: Clearly define the boundaries of your driveway.
Clearly define the boundaries of your driveway. Excavating the ground: Dig to the desired depth, typically 200-250mm for standard residential driveways.
Dig to the desired depth, typically 200-250mm for standard residential driveways. Clearing obstacles: Remove any roots, rocks, or debris to achieve a flat foundation.
Pro tip: Don't cut corners on excavation. Uneven or poorly prepared ground can lead to weed growth and sinking.
A stable sub-base is crucial for bearing the weight of vehicles. Follow these steps: Add the sub-base material: Use MOT Type 1 crushed stone, which compacts well to form a solid base.
Use MOT Type 1 crushed stone, which compacts well to form a solid base. Compact thoroughly: Use a plate compactor to compact the material in layers.
Use a plate compactor to compact the material in layers. Level correctly: Ensure the base slopes slightly to allow proper water runoff.
At Driveway Swindon, we ensure this step is performed with precision to avoid future issues such as sinking or uneven surfaces.
The bedding layer sits between the sub-base and the blocks. Here's how it's done: Spread sharp sand evenly: The sand layer should be approximately 30-50mm thick.
The sand layer should be approximately 30-50mm thick. Level the surface: Use a screed board to create a smooth, even layer.
Tip for DIY-ers: Avoid over-compacting the sand before laying the blocks. It needs to settle with the blocks during the final compaction phase.
This is where your driveway starts to come to life: Start laying blocks from a corner: Work from one corner and maintain straight alignment for a professional finish.
Work from one corner and maintain straight alignment for a professional finish. Check spacing regularly: Keep a consistent gap between blocks for jointing sand later.
Keep a consistent gap between blocks for jointing sand later. Cut blocks for edges: Use a block splitter or angle grinder for precise cuts.
Proper alignment is critical here. A slight misstep can affect the overall pattern.
Once the blocks are laid, it's time to secure them: Compact the blocks: Use a vibrating plate compactor to set the blocks firmly.
Use a vibrating plate compactor to set the blocks firmly. Add kiln-dried sand: Brush sand into the gaps to lock the blocks together. Compact the surface again, repeating until all joints are filled.
This step enhances the driveway's stability and prevents movement.
With the driveway complete, you'll want it to look great and stay in top condition: Seal the surface: A sealant can protect the blocks from stains and enhance color longevity.
A sealant can protect the blocks from stains and enhance color longevity. Schedule regular cleaning: Periodically sweep and wash the driveway to remove dirt and inhibit weed growth.
Periodically sweep and wash the driveway to remove dirt and inhibit weed growth. Inspect annually: Check for any loose or damaged blocks and repair as needed.
At Driveway Swindon, we offer maintenance services to ensure your driveway continues to impress for years to come.
The price of block paving varies depending on factors like driveway size and material choice. On average: Materials: Basic concrete blocks start at £20-£30 per square meter, while premium options like clay or natural stone can cost more.
Basic concrete blocks start at £20-£30 per square meter, while premium options like clay or natural stone can cost more. Labor: Professional installation typically costs £100-£150 per day in Swindon, depending on complexity.
Professional installation typically costs £100-£150 per day in Swindon, depending on complexity. Extras: Drainage systems, edging, and sealant can add to the overall cost.
A professionally installed driveway by Driveway Swindon might seem like a big investment, but the long-term benefits in durability, beauty, and value make it worthwhile.
DIY block paving may seem tempting to save money, but hiring professionals ensures: Expert craftsmanship with long-lasting results. Compliance with building regulations. Proper drainage solutions to prevent water damage. Peace of mind knowing your driveway is built to high standards.
With years of experience, Driveway Swindon has become a trusted name in block paving services, with countless satisfied customers throughout Swindon.
When choosing a contractor, expertise and reliability are paramount. Here's why Driveway Swindon stands out: Local knowledge: We understand Swindon's specific regulations and climate conditions.
We understand Swindon's specific regulations and climate conditions. Unmatched experience: We've successfully completed numerous driveways for homeowners just like you.
We've successfully completed numerous driveways for homeowners just like you. Customer satisfaction: Our clients rave about the quality of our work and our attention to detail.
Our clients rave about the quality of our work and our attention to detail. Tailored solutions: Whether you need classic block paving or permeable options for your eco-friendly home, we've got you covered.
Ready to transform your property with a stunning block paving driveway? Contact Driveway Swindon for a free, no-obligation quote. Call us today or visit our website to learn more about our professional services.
TIME BUSINESS NEWS

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

How to Lay a Block Paving Driveway: Step by Step Guide
How to Lay a Block Paving Driveway: Step by Step Guide

Time Business News

time04-06-2025

  • Time Business News

How to Lay a Block Paving Driveway: Step by Step Guide

A block paving driveway can completely transform your home's curb appeal, enhancing its value and functionality. Whether you're looking for durability, low maintenance, or aesthetic charm, block paving offers it all. But to achieve the best results, proper planning and expert installation are essential. If you're in Swindon, this step-by-step guide will help you understand the process and benefits of installing a block paving driveway. Plus, we'll show you why leaving this project to the professionals at Driveway Swindon is the smartest move. Block paving involves individual stone or concrete blocks interlocked to create a paved surface. These surfaces are known for their strength, style, and versatility. Here's why homeowners in Swindon love block paving: Durable and long-lasting: Properly installed block paving can handle heavy vehicles and resist wear-and-tear for decades. Properly installed block paving can handle heavy vehicles and resist wear-and-tear for decades. Aesthetic variety: Choose from various colors, patterns, and textures to match your style. Choose from various colors, patterns, and textures to match your style. Low maintenance: With occasional cleaning and weed control, your driveway stays pristine. With occasional cleaning and weed control, your driveway stays pristine. Environmental benefit: Permeable options improve drainage and reduce flooding risks. Now, let's break down the process into manageable steps. Before starting any construction, you'll need a solid plan. Here's what to consider: Measure the area: Determine the size of the driveway you need. Determine the size of the driveway you need. Choose materials: Block paving stones come in different materials, from concrete to clay. Consider aesthetics, durability, and your budget. Block paving stones come in different materials, from concrete to clay. Consider aesthetics, durability, and your budget. Decide on the pattern: Common patterns include herringbone, stretcher bond, and basketweave. Each offers unique visual appeal and load distribution advantages. Common patterns include herringbone, stretcher bond, and basketweave. Each offers unique visual appeal and load distribution advantages. Account for drainage: UK regulations require driveways to have proper drainage. Permeable blocks are a great option to comply with sustainable drainage systems (SuDS). At Driveway Swindon, our experts can help you design a driveway tailored to your needs while meeting local planning regulations. Proper site preparation ensures the driveway's longevity. The process includes: Marking the area: Clearly define the boundaries of your driveway. Clearly define the boundaries of your driveway. Excavating the ground: Dig to the desired depth, typically 200-250mm for standard residential driveways. Dig to the desired depth, typically 200-250mm for standard residential driveways. Clearing obstacles: Remove any roots, rocks, or debris to achieve a flat foundation. Pro tip: Don't cut corners on excavation. Uneven or poorly prepared ground can lead to weed growth and sinking. A stable sub-base is crucial for bearing the weight of vehicles. Follow these steps: Add the sub-base material: Use MOT Type 1 crushed stone, which compacts well to form a solid base. Use MOT Type 1 crushed stone, which compacts well to form a solid base. Compact thoroughly: Use a plate compactor to compact the material in layers. Use a plate compactor to compact the material in layers. Level correctly: Ensure the base slopes slightly to allow proper water runoff. At Driveway Swindon, we ensure this step is performed with precision to avoid future issues such as sinking or uneven surfaces. The bedding layer sits between the sub-base and the blocks. Here's how it's done: Spread sharp sand evenly: The sand layer should be approximately 30-50mm thick. The sand layer should be approximately 30-50mm thick. Level the surface: Use a screed board to create a smooth, even layer. Tip for DIY-ers: Avoid over-compacting the sand before laying the blocks. It needs to settle with the blocks during the final compaction phase. This is where your driveway starts to come to life: Start laying blocks from a corner: Work from one corner and maintain straight alignment for a professional finish. Work from one corner and maintain straight alignment for a professional finish. Check spacing regularly: Keep a consistent gap between blocks for jointing sand later. Keep a consistent gap between blocks for jointing sand later. Cut blocks for edges: Use a block splitter or angle grinder for precise cuts. Proper alignment is critical here. A slight misstep can affect the overall pattern. Once the blocks are laid, it's time to secure them: Compact the blocks: Use a vibrating plate compactor to set the blocks firmly. Use a vibrating plate compactor to set the blocks firmly. Add kiln-dried sand: Brush sand into the gaps to lock the blocks together. Compact the surface again, repeating until all joints are filled. This step enhances the driveway's stability and prevents movement. With the driveway complete, you'll want it to look great and stay in top condition: Seal the surface: A sealant can protect the blocks from stains and enhance color longevity. A sealant can protect the blocks from stains and enhance color longevity. Schedule regular cleaning: Periodically sweep and wash the driveway to remove dirt and inhibit weed growth. Periodically sweep and wash the driveway to remove dirt and inhibit weed growth. Inspect annually: Check for any loose or damaged blocks and repair as needed. At Driveway Swindon, we offer maintenance services to ensure your driveway continues to impress for years to come. The price of block paving varies depending on factors like driveway size and material choice. On average: Materials: Basic concrete blocks start at £20-£30 per square meter, while premium options like clay or natural stone can cost more. Basic concrete blocks start at £20-£30 per square meter, while premium options like clay or natural stone can cost more. Labor: Professional installation typically costs £100-£150 per day in Swindon, depending on complexity. Professional installation typically costs £100-£150 per day in Swindon, depending on complexity. Extras: Drainage systems, edging, and sealant can add to the overall cost. A professionally installed driveway by Driveway Swindon might seem like a big investment, but the long-term benefits in durability, beauty, and value make it worthwhile. DIY block paving may seem tempting to save money, but hiring professionals ensures: Expert craftsmanship with long-lasting results. Compliance with building regulations. Proper drainage solutions to prevent water damage. Peace of mind knowing your driveway is built to high standards. With years of experience, Driveway Swindon has become a trusted name in block paving services, with countless satisfied customers throughout Swindon. When choosing a contractor, expertise and reliability are paramount. Here's why Driveway Swindon stands out: Local knowledge: We understand Swindon's specific regulations and climate conditions. We understand Swindon's specific regulations and climate conditions. Unmatched experience: We've successfully completed numerous driveways for homeowners just like you. We've successfully completed numerous driveways for homeowners just like you. Customer satisfaction: Our clients rave about the quality of our work and our attention to detail. Our clients rave about the quality of our work and our attention to detail. Tailored solutions: Whether you need classic block paving or permeable options for your eco-friendly home, we've got you covered. Ready to transform your property with a stunning block paving driveway? Contact Driveway Swindon for a free, no-obligation quote. Call us today or visit our website to learn more about our professional services. TIME BUSINESS NEWS

Psyence BioMed Announces USD$500,000 Follow-On Investment in PsyLabs and Global Ibogaine Supply Agreement
Psyence BioMed Announces USD$500,000 Follow-On Investment in PsyLabs and Global Ibogaine Supply Agreement

Yahoo

time15-04-2025

  • Yahoo

Psyence BioMed Announces USD$500,000 Follow-On Investment in PsyLabs and Global Ibogaine Supply Agreement

New York, New York--(Newsfile Corp. - April 15, 2025) - Psyence Biomedical Ltd. (NASDAQ: PBM) ("Psyence BioMed" or the "Company") today announced a strategic follow-on investment of USD $500,000 into PsyLabs, a privately-held company specializing in the production of psychedelic active pharmaceutical ingredients (APIs) and extracts for research, clinical trials, and drug development. This follow-on investment underscores Psyence BioMed's commitment to building a vertically integrated, multi-asset psychedelics biotech platform with robust supply chain security and clinical development capabilities. This new capital investment builds on the exclusive, royalty-bearing IP licensing agreement formalized between the two companies in September 2024, following an initial investment where Psyence BioMed acquired an 11.13% equity stake in PsyLabs. Under the terms of that agreement, PsyLabs supplies Psyence BioMed with pharmaceutical-grade, EU-GMP, nature-derived (non-synthetic) psilocybin for use in future clinical trials and eventual commercialization in substance use disorders (SUD). In parallel with this financial commitment, Psyence BioMed has secured an exclusive right of first refusal in respect of the worldwide supply of pharmaceutical-grade, nature-derived Ibogaine. Under this agreement, PsyLabs will grant Psyence BioMed a right of first refusal to acquire the exclusive rights to a dedicated supply of Ibogaine for evaluation in the treatment of SUD, including Alcohol Use Disorder (AUD). This exclusive partnership further strengthens Psyence BioMed's integrated development strategy, ensuring access to high-quality psychedelic compounds to support its growing clinical pipeline and diversification into multiple therapeutic areas. Ibogaine, a naturally occurring psychoactive substance derived from the Tabernanthe iboga plant, has shown promise in early-stage research for its unique ability to interrupt SUDs, offering a novel approach to addiction treatment. Existing treatment options for SUDs and AUD remain limited in effectiveness, highlighting the urgent need for new solutions. "We are thrilled to strengthen our partnership with PsyLabs through both our financial investment and this opportunity to acquire exclusive Ibogaine supply rights," said Dr. Neil Maresky, CEO of Psyence BioMed. "Ibogaine holds significant potential as part of a new wave of therapeutics targeting some of the most challenging conditions in mental health. With this agreement, we are well positioned to accelerate our research efforts and bring much-needed innovation to patients worldwide." Tony Budden, Chief Executive Officer at PsyLabs, added: "This expanded collaboration with Psyence BioMed reflects our shared vision for advancing the science and development of nature-derived psychedelic medicines. By combining our manufacturing expertise with Psyence BioMed's clinical development capabilities, we are creating a powerful platform to explore the full potential of Ibogaine and psilocybin in addressing addiction and mental health disorders." Additional details about PsyLabs are available at An overview of the company's operations and manufacturing capabilities can be viewed in this video. These strategic initiatives and investments align with Psyence BioMed's vision to develop a diversified pipeline of psychedelic-based therapeutics supported by strong supply chain partnerships and proprietary intellectual property, as the Company advances toward becoming a leading, vertically integrated psychedelic biotech company. The follow-on investment shall be subject to the conclusion of a definitive right of first refusal agreement between the parties based on the salient terms already reduced to writing and other customary closing and suspensive conditions, including regulatory approvals (if any). About Psyence BioMed: Psyence BioMed is one of the few multi-asset, vertically integrated biopharmaceutical companies specializing in psychedelic-based therapeutics. It is the first life sciences biotechnology company focused on developing nature-derived (non-synthetic) psilocybin-based psychedelic medicine to be listed on Nasdaq. Psyence is dedicated to addressing unmet mental health needs, particularly in palliative care. The name 'Psyence' merges 'psychedelics' and 'science,' reflecting the company's commitment to an evidence-based approach in developing safe, effective, and FDA-approved nature-derived psychedelic treatments for a broad range of mental health disorders. Learn more at and on LinkedIn. About PsyLabs PsyLabs is a psychedelic Active Pharmaceutical Ingredient (API) development company, federally licensed to cultivate, extract, and export psilocybin mushrooms and other psychedelic compounds including psilocin, mescaline, ibogaine, and dimethyltryptamine (DMT) to legal medical and research markets. The company has successfully exported psilocybin products to Canada, the UK, Portugal, and Slovenia, and supplies purified extracts to its UK-based CMO partner. PsyLabs operates from an ISO 22000-certified facility audited by the British Standards Institution, ensuring the highest standards of safety and traceability. With a focus on natural compound purification, regulatory support, and global distribution, PsyLabs is expanding its product pipeline to include ibogaine and other next-generation Contact Information for Psyence Biomedical Ltd. Email: ir@ Media Inquiries: media@ General Information: info@ Phone: +1 416-477-1708 Investor Contact: Michael Kydd Investor Relations Advisor michael@ Forward Looking Statements This communication contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about future financial and operating results, our plans, objectives, expectations, and intentions with respect to future operations, products and services; and other statements identified by words such as "will likely result," "are expected to," "will continue," "is anticipated," "estimated," "believe," "intend," "plan," "projection," "outlook" or words of similar meaning. Forward-looking statements in this communication include statements regarding the acquisition of exclusive Ibogaine supply rights, the growing of Psyence BioMed's clinical pipeline, and the diversification of its therapeutic areas. These forward-looking statements are based on a number of assumptions, including the assumption that there will be no delays in the execution of a definition right of first refusal agreement, that Psyence BioMed shall exercise its exclusive Ibogaine supply acquisition rights, and that the demand for psychedelic-assisted therapy will include the use of Ibogaine. There can be no assurance that the Company will continue to maintain compliance with Nasdaq's continued listing requirements. There are numerous risks and uncertainties that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, among others: (i) delays in the execution of the right of first refusal agreement; (ii) the ability of Psyence BioMed to maintain the listing of its common shares and warrants on Nasdaq; (iii) volatility in the price of the securities of Psyence BioMed due to a variety of factors, including the recent share consolidation, changes in the competitive and highly regulated industries in which Psyence BioMed operates, variations in performance across competitors, changes in laws and regulations affecting Psyence BioMed's business and changes in Psyence BioMed's capital structure. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the "Risk Factors" section of the Company's final prospectus (File No. 333-284444) filed with the Securities and Exchange Commission (the "SEC") on January 24, 2025 and other documents filed by Psyence BioMed from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Actual results and future events could differ materially from those anticipated in such statements. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Except as required by law, Psyence BioMed does not intend to update these forward-looking statements. The Company does not make any medical, treatment or health benefit claims about its proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocybin, psilocybin analogues, or other psychedelic compounds or nutraceutical products. The efficacy of such products has not been confirmed by authorized clinical research. There is no assurance that the use of psilocybin, psilocybin analogues, or other psychedelic compounds or nutraceuticals can diagnose, treat, cure or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. The Company has not conducted clinical trials for the use of the proposed products. Any references to quality, consistency, efficacy, and safety of potential products do not imply that the Company has verified such in clinical trials or that the Company will complete such trials. If the Company cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the Company's performance and operations. To view the source version of this press release, please visit Sign in to access your portfolio

Psyence Biomed Provides Progress Update on PsyLabs E.U. Good Manufacturing Practices (GMP) Certified Active Pharmaceutical Ingredient (API) Development
Psyence Biomed Provides Progress Update on PsyLabs E.U. Good Manufacturing Practices (GMP) Certified Active Pharmaceutical Ingredient (API) Development

Yahoo

time17-10-2024

  • Yahoo

Psyence Biomed Provides Progress Update on PsyLabs E.U. Good Manufacturing Practices (GMP) Certified Active Pharmaceutical Ingredient (API) Development

PsyLabs to exclusively supply Psyence Biomed with high purity, pharmaceutical grade psilocybin for its second development indication, Alcohol Use Disorder, as previously announced NEW YORK, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence Biomed" or the "Company") is pleased to provide an update on its previously-announced pending strategic acquisition of an equity stake in PsyLabs, and progress with PsyLabs' collaboration with its contract drug manufacturing organization (CDMO). This collaboration is key to advancing the development of PsyLabs' nature-derived psychedelic active pharmaceutical ingredients (APIs) towards E.U. Good Manufacturing Practices (GMP) certification. In September 2024, Psyence Biomed entered into a worldwide, exclusive royalty-bearing IP licensing agreement with PsyLabs for pharmaceutical-grade, EU GMP certified, nature-derived psilocybin to be evaluated in future clinical trials as a potential treatment for Alcohol Use Disorder (AUD) and other Substance Use Disorders (SUDs), and for commercial supply, if approved. Following the successful export of its psilocybin extract to its CDMO in the UK, PsyLabs has now entered phase two of its development process. The CDMO has commenced work on upscaling the purification process to validate its commercial viability, ensuring that the extraction methodology developed by PsyLabs can be efficiently scaled for larger production volumes. This critical phase will confirm that the methods used to achieve PsyLabs' high-purity psilocybin can be replicated on a commercial scale, setting the foundation for E.U. GMP certification. This milestone represents significant progress in PsyLabs' journey to produce E.U. GMP certified APIs. The ability to scale the extraction process while maintaining high purity levels is essential for meeting the rigorous demands of global health regulators and advancing through Phase III clinical trials. PsyLabs' collaboration with its CDMO is designed to ensure that PsyLabs' APIs are commercially viable and meet the highest quality standards, providing a faster route to market for psychedelic-based therapies. Psyence Biomed's pending acquisition of an equity stake in PsyLabs continues to align with its strategy of securing access to pharmaceutical-grade, naturally derived APIs that can serve as the foundation for future clinical trials and FDA-approved drug development. This update marks another important step in solidifying a consistent supply of high-purity psilocybin. As this next phase progresses, Psyence Biomed remains confident that PsyLabs is on track to produce GMP certified, nature-derived psychedelic APIs. These developments underscore Psyence Biomed's commitment to innovation and leadership in the psychedelic sector. PsyLabs' proprietary methods, combined with strategic collaborations like the one with its CDMO, will continue to provide Psyence Biomed with a competitive edge in bringing next-generation mental health treatments to market. 'Our strategic acquisition of an equity stake in PsyLabs, when completed later this year, will transition Psyence Biomed into a fully vertically integrated developer of psilocybin-based therapeutics that address significant unmet needs in mental health and addiction,' said Dr. Neil Maresky, Chief Executive Officer of Psyence Biomed. 'PsyLabs' continued progress toward the production of E.U. GMP certified APIs is a critical step going forward, and we are very pleased with their progress to date. We look forward to a long and mutually beneficial partnership with PsyLabs as we advance a psilocybin-based therapeutic as a potential treatment for AUD.' Tony Budden, Chief Executive Officer of PsyLabs, said 'We believe our proprietary extraction process will create the highest purity psilocybin available on the market, at a time when regulatory agencies around the world are placing greater emphasis on purity in psychedelic-based drug development programs. Psyence Biomedical Ltd. (Nasdaq: PBM) is one of the world's few biopharmas with a focus on psychedelic-based pharmaceutical therapeutics. As the first life science biotechnology company developing nature-derived (non-synthetic) psilocybin-based psychedelic medicine to be listed on Nasdaq, Psyence is initially working to address the unmet needs of patients who suffer from mental health disorders in the context of Palliative Care. The name 'Psyence' combines the words 'psychedelics' and 'science' to affirm Psyence Biomed's commitment to an evidence-based approach to innovation as it works to develop safe and effective, FDA-approved, nature-derived psychedelic therapeutics to treat a broad range of mental health disorders. Learn more at and on LinkedIn. Email: ir@ Inquiries: media@ Information: info@ +1 416-477-1708 Jeremy FefferManaging DirectorLifeSci Advisorsjfeffer@ This communication contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about future financial and operating results, our plans, objectives, expectations and intentions with respect to future operations, products and services; and other statements identified by words such as "will likely result," "are expected to," "will continue," "is anticipated," "estimated," "believe," "intend," "plan," "projection," "outlook" or words of similar meaning. Forward-looking statements in this communication include statements regarding the fulfilment of the conditions to the closing of the strategic acquisition of an equity stake in PsyLabs (the ""), access to the capital and liquidity required for Psyence Biomed to execute on the AUD strategy and PsyLabs' ability to successfully deliver its intended drug product. These forward-looking statements are based on a number of assumptions, including the assumptions that the parties will obtain all such regulatory, corporate, shareholder and other approvals as may be required to implement the Acquisition, the continuation of PsyLabs' product development strategy as referred to in this news release on schedule, and the safety and effectiveness of psilocybin as a treatment option for AUD. There are numerous risks and uncertainties that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, among others: (i) the inability to complete the Acquisition; (ii) the inability to recognize the anticipated benefits of the Acquisition (iii) the ability of PsyLabs to execute its obligations in respect of its product development objectives; (iv) changes in applicable laws which may impact drug development, clinical trials and/or the conducting thereof; (v) Psyence Biomed's ability to obtain regulatory approval for the proposed product candidate, and any related restrictions or limitations of any approved products; (vi) the ability of Psyence Biomed to maintain the listing of its common shares and warrants on Nasdaq; and (vii) volatility in the price of the securities of Psyence Biomed due to a variety of factors, including changes in the competitive and highly regulated industries in which Psyence Biomed operates, variations in performance across competitors, changes in laws and regulations affecting Psyence Biomed's business and changes in Psyence Biomed's capital structure. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the "Risk Factors" section of the final prospectus (File No. 333 276973) filed with the Securities and Exchange Commission on August 30, 2024 and other documents filed by the Company from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Actual results and future events could differ materially from those anticipated in such information. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Except as required by law, the Company does not intend to update these forward-looking statements. The Company makes no medical, treatment or health benefit claims about the Company's proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocybin, psilocybin analogues, or other psychedelic compounds or nutraceutical products. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocybin, psilocybin analogues, or other psychedelic compounds or nutraceuticals can diagnose, treat, cure or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. The Company has not conducted clinical trials for the use of its proposed products. Any references to quality, consistency, efficacy, and safety of potential products do not imply that the Company verified such in clinical trials or that the Company will complete such trials. If the Company cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the Company's performance and operations.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store